A detailed history of Black Rock Inc. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,134,050 shares of LRMR stock, worth $11.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,134,050
Previous 2,338,862 34.0%
Holding current value
$11.9 Million
Previous $17.8 Million 28.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.33 - $9.89 $5.03 Million - $7.86 Million
795,188 Added 34.0%
3,134,050 $22.7 Million
Q1 2024

May 10, 2024

BUY
$4.2 - $13.28 $2.82 Million - $8.91 Million
670,817 Added 40.22%
2,338,862 $17.8 Million
Q4 2023

Feb 13, 2024

BUY
$2.35 - $4.71 $374,190 - $749,973
159,230 Added 10.55%
1,668,045 $7.59 Million
Q3 2023

Nov 13, 2023

BUY
$3.08 - $4.49 $217,238 - $316,688
70,532 Added 4.9%
1,508,815 $5.96 Million
Q2 2023

Aug 11, 2023

BUY
$3.13 - $5.27 $3.49 Million - $5.88 Million
1,115,152 Added 345.11%
1,438,283 $4.5 Million
Q1 2023

May 12, 2023

BUY
$4.0 - $6.68 $123,252 - $205,830
30,813 Added 10.54%
323,131 $1.46 Million
Q4 2022

Feb 13, 2023

BUY
$2.73 - $5.08 $151,656 - $282,204
55,552 Added 23.46%
292,318 $1.21 Million
Q3 2022

Nov 14, 2022

SELL
$1.53 - $3.64 $8,173 - $19,444
-5,342 Reduced 2.21%
236,766 $757,000
Q2 2022

Aug 12, 2022

SELL
$1.9 - $3.98 $7,121 - $14,917
-3,748 Reduced 1.52%
242,108 $475,000
Q1 2022

May 12, 2022

BUY
$3.65 - $10.84 $3,500 - $10,395
959 Added 0.39%
245,856 $996,000
Q4 2021

Feb 10, 2022

BUY
$8.86 - $13.47 $26,845 - $40,814
3,030 Added 1.25%
244,897 $2.64 Million
Q3 2021

Nov 09, 2021

SELL
$9.61 - $15.11 $96,417 - $151,598
-10,033 Reduced 3.98%
241,867 $2.79 Million
Q2 2021

Aug 11, 2021

BUY
$8.0 - $15.2 $2.02 Million - $3.83 Million
251,900 New
251,900 $2.47 Million

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $164M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.